News & Updates

A phase III study presented at EADV 2023 demonstrated the similarity between SB17, a human monoclonal antibody and proposed ustekinumab biosimilar, and reference ustekinumab for the treatment of moderate-to-severe plaque psoriasis.

In patients with rheumatoid arthritis (RA), use of systemic glucocorticoids (GC) is associated with a time- and dose-dependent increase in risk of major adverse cardiovascular events (MACE), a population-based real-world study has shown. On long-term follow-up, a prednisolone dose of ≥5 mg/day is associated with a doubled risk of MACE vs no GC use, and no safe duration of use is found for this daily GC dose.

In the treatment of select patients with rheumatoid arthritis (RA), otilimab is neither better than placebo nor noninferior to sarilumab in terms of the proportion of patients achieving an American College of Rheumatology ≥20 percent response (ACR20), according to the results of the phase III ContRAst 3 study.

Combination treatment with glucocorticoid (GC) plus hydroxychloroquine appears to yield more favourable outcomes than GC alone in the treatment of systemic lupus erythematosus (SLE) rash, while having a good safety profile, according to a study.

Following the switch from combination therapy to monotherapy, rheumatoid arthritis (RA) patients with overall lower disease activity (LDA) have higher odds of achieving and remaining in Simplified Disease Activity Index (SDAI) remission/LDA, suggests a study.